drugset / Trial / NCT02283814

A Open-label, Drug Interaction Study Between Eslicarbazepine Acetate and Topiramate

NCT02283814

Phase 1 Completed 32 enrolled Bial - Portela C S.A.
RandomizedParallel-groupOpen-labelTreatment

Summary

Single centre, open-label, multiple doses, one-sequence design study in two parallel groups of healthy volunteers

Timeline

Start
2007-01
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Eslicarbazepine acetate Unknown 600 mg
Subject Eslicarbazepine acetate Unknown 1200 mg
Subject Topiramate Small molecule 100 mg
Subject Topiramate Small molecule 200 mg

Indications